Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

What Are Genital Warts? What Causes Genital Warts?
Genital warts are also called venereal warts or condylomata acuminate. Genital warts are one of the most common kinds of STDs (sexually transmitted diseases) or STIs (sexually transmitted infections). According to Medilexicon"s medical dictionary, a genital wart is "a contagious projecting warty growth on the external genitals or at the anus, consisting of fibrous overgrowths covered by thickened epithelium showing koilocytosis, due to sexual contact with infection by human papillomavirus; it is usually benign, although malignant change has been reported, associated with particular types of the virus."
generic viagra online
Registeration For The American Association Of Kidney Patients' National Convention Now Open!
Registration for the American Association of Kidney Patients" (AAKP) 36th Annual National Convention is now open. The Convention takes place Sept. 3-5 at the Hyatt Regency Denver in Denver, Colo. The Annual Convention provides patients, family members and health care professionals the opportunity to learn about important issue affecting kidney patients. During this three-day event, attendees participate in educational sessions for those with chronic kidney disease (CKD) to long-term dialysis and transplant patients. Participants also learn about various treatments for each stage of kidney disease.
News of the day
Facing Congressional Squabbling, President Pushes For Reform
The press for health care reform hit a snag this week as Congress sputtered to resolve its differences, but President Barack Obama continues his call, almost daily, to continue to try to change the system, The New York Times reports.
Sexual Health

Dynavax Awarded Grant To Support Development Of TLR Inhibitors In Skin Diseases

Dynavax Technologies Corporation (Nasdaq:DVAX) announced the award of a Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID). This grant will support the preclinical development of Dynavax"s first-in-class oligonucleotide-based Toll-like Receptor (TLR) inhibitors for use in inflammatory skin diseases such as psoriasis, cutaneous lupus, and dermatomyositis. This new two-year $700,000 grant is in addition to a $1.8 million grant awarded in 2008. "In addition to validating our proprietary technology, this new grant supports the preclinical studies for our TLR inhibitors, which represent a novel therapeutic approach for the treatment of inflammatory skin disorders," commented Robert L. Coffman, Ph.D., Vice President and Chief Scientific Officer of Dynavax Technologies. "Grant funding and partnerships with leading pharmaceutical companies help us advance the development of our TLR-based products targeting significant unmet medical needs." For more information about Dynavax"s TLR inhibitor program, visit here. Dynavax Technologies Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009